Seiler V
Arzneimittelforschung. 1983;33(4A):656-9.
41 patients with radiographically verified degenerative joint disease of the hand who had at least one acutely inflamed Heberden node entered into the study. 22 patients were treated with 300 mg N-(2,6-dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen) per day for 4 weeks and 19 patients received placebo. Measures of efficacy were: the number of painful joints on both hands, an index of pain, the number of inflamed Heberden nodes and the grip strength (mmHg). Disease activity was similar in both groups at the beginning of the study. Analyses after one week of treatment and at the last observation at the conclusion of the study revealed significant differences in favor of meclofenamate sodium. This indicates that meclofenamate sodium treatment of degenerative joint disease of the hands is significantly superior to placebo. The reduction of the number of inflamed Heberden nodes demonstrates the anti-inflammatory effect of meclofenamate sodium, while the reduction of painful joints and the decreased pain index is evidence of the analgesic effect of this drug. The increase in grip strength indicates an improvement of function. The results further demonstrate the early onset of treatment effect with meclofenamate sodium. Meclofenamate sodium was well tolerated.
41例经影像学证实患有手部退行性关节病且至少有一个急性炎症性赫伯登结节的患者进入了该研究。22例患者每天接受300毫克N-(2,6-二氯间甲苯基)邻氨基苯甲酸的钠盐（甲氯芬那酸钠，甲氯灭酸）治疗，持续4周，19例患者接受安慰剂治疗。疗效指标包括：双手疼痛关节的数量、疼痛指数、炎症性赫伯登结节的数量以及握力（毫米汞柱）。在研究开始时，两组的疾病活动度相似。治疗一周后以及研究结束时的最后一次观察分析显示，甲氯芬那酸钠组有显著差异。这表明甲氯芬那酸钠治疗手部退行性关节病明显优于安慰剂。炎症性赫伯登结节数量的减少证明了甲氯芬那酸钠的抗炎作用，而疼痛关节数量的减少和疼痛指数的降低是该药物镇痛作用的证据。握力的增加表明功能有所改善。结果进一步证明了甲氯芬那酸钠治疗效果的早期出现。甲氯芬那酸钠耐受性良好。
